rs11045392 - PDE3A: rheumatoid arthritis response

Key takeaways

  • The rs11045392 variant is associated with response to TNF-alpha inhibitors in rheumatoid arthritis.
  • Effect size 3.3 p=2e-6 from a GWAS catalog study of 196 participants.
  • No conflicting findings reported.

Key takeaways

  • Response to TNF-alpha inhibitors in rheumatoid arthritis - the variant is associated with a reported effect size of 3.3 p=2e-6 in about 196 individuals
  • The association comes from a GWAS catalog study with n=196 and p=2e-6

What the research says The rs11045392 variant is associated with response to TNF-alpha inhibitors in rheumatoid arthritis [PMID 22569225]. This effect size of 3.3 and p-value of 2e-6 was reported in a GWAS catalog association study.

Reported associations

  • Response to TNF-alpha inhibitors in rheumatoid arthritis - the variant is associated with a reported effect size of 3.3 p=2e-6 in about 196 individuals [PMID 22569225].

Evidence quality The supplied study is a GWAS catalog association reporting an effect size of 3.3 and p-value of 2e-6 from 196 participants. No conflicting findings are reported. No lifestyle considerations on file for this variant.

Frequently asked questions

What does rs11045392 mean?

rs11045392 is a genetic change in the PDE3A gene that appears linked to a higher response to TNF-alpha inhibitors in rheumatoid arthritis.

Is this variant dangerous?

The study shows an association with drug response but does not indicate increased disease risk or harm.

Can I test for rs11045392?

Testing is possible through genetic testing services that include PDE3A variants.